The P-III trial (AEGEAN) evaluating Imfinzi (1500mg) + CT vs PBO + CT in 802 patients with resectable Stage IIA-IIIB NSCLC, irrespective of PD-L+1 expression at 264 centers in 25+ countries incl. in the US, Canada, EU, South America & Asia
The results showed that patients treated with Imfinzi + CT & as adjuvant monotx. achieved an improvement in EFS, results from the final pCR & mPR analyses were consistent with prior positive results, was well tolerated with no new safety concerns in the neoadjuvant & adjuvant settings
The combination therapy was consistent with the known profile. Imfinzi was approved in the US, EU, Japan, China & many other countries globally for extensive-stage SCLC, based on P-III trial (CASPIAN) results
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receives EU Approval for Advanced Liver and Non-Small Cell Lung Cancer
